Evidence map›Paper›PMID 40163507›Full record

ArticlePloS one2025

Decoding oncogenic secrets of regulator of chromosome condensation 1: A breakthrough mechanistic evidence from breast and lung cancer models.

Mohamed El-Tanani, Shakta Mani Satyam, Syed Arman Rabbani, Razan M Obeidat, Yahia El-Tanani, Alaa A A Aljabali, Taher Hatahet

Abstract read
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Berberine shows potential in mitigating PMApoptosis : an international journal on programmed cell death · 2026
    Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mohamed El-TananiRAK College of Pharmacy, RAK Medical and Health Sciences University, Ras Al Khaimah, United Arab Emirates.
Shakta Mani SatyamDepartment of Pharmacology, RAK College of Medical Sciences, RAK Medical and Health Sciences University, Ras Al Khaimah, United Arab Emirates.ORCID 0000-0001-5761-2073
Syed Arman RabbaniDepartment of Clinical Pharmacy, RAK College of Pharmacy, Ras Al Khaimah Medical and Health Sciences University, Ras Al Khaimah, United Arab Emirates.
Razan M ObeidatPharmacological and Diagnostic Research Center, Faculty of Pharmacy, Al-Ahliyya Amman University, Amman, Jordan.
Yahia El-TananiRoyal Cornwall Hospital Trust, NHS, London, United Kingdom.
Alaa A A AljabaliDepartment of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Yarmouk University, Irbid, Jordan.ORCID 0000-0002-9519-6338
Taher HatahetDepartment of Pharmaceutical Technology, Queen's University Belfast, Belfast, United Kingdom.ORCID 0000-0003-0171-3304

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Regulator of Chromosome Condensation 1 (RCC1), a master regulator of cell cycle progression, chromatin structure, and nuclear transport, emerges as a powerful driver of cancer progression. Elevated RCC1 expression in breast and lung cancers is closely tied to enhanced tumor cell survival, proliferation, and metastasis, positioning it as a promising therapeutic target. This study unveils RCC1's pivotal role in cancer biology by silencing its expression in MDA-MB-231 (breast cancer) and A549 (lung cancer) cell lines using shRNA. RCC1 knockdown dramatically reduced cell viability, colony formation, and motility, while inducing apoptosis, as evidenced by increased apoptotic markers and reduced anti-apoptotic Bcl2 expression. Gene expression analysis revealed downregulation of cell cycle and DNA repair pathways, highlighting RCC1's critical role in sustaining oncogenic mechanisms. These findings underscore RCC1 as a gatekeeper of tumor survival, capable of resisting apoptosis and promoting metastasis. Targeting RCC1 offers a dual advantage: disrupting cancer growth and enhancing apoptotic pathways, creating an exciting opportunity for precision therapies. By illuminating RCC1's integration into survival networks, this study not only advances our understanding of cancer biology but also lays the groundwork for innovative treatments aimed at halting cancer progression and metastasis.

Indexed as

Breast NeoplasmsCell Cycle ProteinsGuanine Nucleotide Exchange FactorsLung NeoplasmsNuclear ProteinsA549 CellsApoptosisCell Line, TumorCell MovementCell ProliferationCell SurvivalFemaleGene Expression Regulation, NeoplasticHumansCell Cycle ProteinsGuanine Nucleotide Exchange FactorsNuclear ProteinsRCC1 protein, human

Identifiers

PMID40163507
PMCPMC11957297

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.